1. Home
  2. RYTM vs ELPC Comparison

RYTM vs ELPC Comparison

Compare RYTM & ELPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • ELPC
  • Stock Information
  • Founded
  • RYTM 2008
  • ELPC 1954
  • Country
  • RYTM United States
  • ELPC Brazil
  • Employees
  • RYTM 283
  • ELPC N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • ELPC Electric Utilities: Central
  • Sector
  • RYTM Health Care
  • ELPC Utilities
  • Exchange
  • RYTM Nasdaq
  • ELPC Nasdaq
  • Market Cap
  • RYTM 6.9B
  • ELPC 6.1B
  • IPO Year
  • RYTM 2017
  • ELPC N/A
  • Fundamental
  • Price
  • RYTM $102.12
  • ELPC $8.36
  • Analyst Decision
  • RYTM Strong Buy
  • ELPC
  • Analyst Count
  • RYTM 13
  • ELPC 0
  • Target Price
  • RYTM $101.92
  • ELPC N/A
  • AVG Volume (30 Days)
  • RYTM 550.8K
  • ELPC 2.5K
  • Earning Date
  • RYTM 11-04-2025
  • ELPC 01-01-0001
  • Dividend Yield
  • RYTM N/A
  • ELPC 4.78%
  • EPS Growth
  • RYTM N/A
  • ELPC 30.24
  • EPS
  • RYTM N/A
  • ELPC 0.19
  • Revenue
  • RYTM $156,287,000.00
  • ELPC $4,381,150,343.00
  • Revenue This Year
  • RYTM $44.69
  • ELPC N/A
  • Revenue Next Year
  • RYTM $63.53
  • ELPC $6.59
  • P/E Ratio
  • RYTM N/A
  • ELPC $11.46
  • Revenue Growth
  • RYTM 53.55
  • ELPC 8.47
  • 52 Week Low
  • RYTM $45.91
  • ELPC $5.04
  • 52 Week High
  • RYTM $106.52
  • ELPC $8.87
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 60.62
  • ELPC 55.77
  • Support Level
  • RYTM $101.45
  • ELPC $8.08
  • Resistance Level
  • RYTM $106.52
  • ELPC $8.20
  • Average True Range (ATR)
  • RYTM 3.12
  • ELPC 0.04
  • MACD
  • RYTM -0.43
  • ELPC -0.01
  • Stochastic Oscillator
  • RYTM 65.84
  • ELPC 90.00

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About ELPC Companhia Paranaense de Energia (COPEL) (each representing four (4))

Cia Paranaense De Energia Copel is engaged in the areas of generation, transmission, commercialization and distribution of energy. It operates a comprehensive and effective electrical system with its own generating plants, transmission lines, substations, electrical lines and grids of the distribution system. The company's reportable segments include Power generation and transmission, Power distribution, GAS, Power sale, Services, and Holding. The majority of its revenue is generated from the Power generation and transmission segment under which it produces electricity from hydraulic, wind, and thermal projects and provides services of transmission and transformation of electric power and other related services.

Share on Social Networks: